Considering the active downregulation of KP-related genes by Dinaciclib, we investigated whether this CDKi is able to inhibit or reverse IFNγ-induced IDO1 upregulation in GBM and HNSCC cells on a protein level. The gene discussed is IFNG; the disease is head and neck squamous cell carcinoma.